Flublok®
QUADRIVALENT
Influenza Vaccine

FLUBLOK QUADRIVALENT VACCINE:

PROVEN TO PREVENT MORE CASES OF INFLUENZA IN ADULTS 50+[1,2]

Compared with a standard-dose quadrivalent inactivated influenza vaccine[1]

According to a study published in the *New England Journal of Medicine* in June 2017,

FLUBLOK QUADRIVALENT VACCINE PROVIDED:

30%
BETTER PROTECTION
from influenza disease

PRIMARY ENDPOINT:
rtPCR[a]-confirmed, protocol-defined, influenza-like illness due to any influenza virus type or subtype[1,2]

43%
BETTER PROTECTION
from influenza disease

SECONDARY ENDPOINT:
Culture-confirmed, protocol-defined, influenza-like illness due to any influenza virus type or subtype[1,2]

THE BENEFITS OF FLUBLOK QUADRIVALENT VACCINE

- Contains 3x the HA[b] of standard-dose quadrivalent influenza vaccine[3]
- Comparable safety profile to a standard-dose quadrivalent influenza vaccine[2]
- Recombinant hemagglutinin vaccine designed to replicate the HA exactly[4]
- Approved for patients 18 years of age and older[1]

CHOOSE FLUBLOK QUADRIVALENT VACCINE TO HELP PROTECT YOUR PATIENTS 50+

[a]rtPCR = Reverse transcriptase polymerase chain reaction.
[b]HA = Hemagglutinin antigen.

Please click here to see Important Safety Information.

SANOFI PASTEUR

IMPORTANT SAFETY INFORMATION FOR FLUBLOK QUADRIVALENT VACCINE

Flublok Quadrivalent vaccine should not be administered to anyone who has had a severe allergic reaction (eg, anaphylaxis) to a previous dose of the vaccine or any component of the vaccine.

If Guillain-Barré syndrome has occurred within 6 weeks following previous influenza vaccination, the decision to give Flublok Quadrivalent vaccine should be based on careful consideration of the potential benefits and risks.

The most common local adverse reactions to Flublok Quadrivalent vaccine include tenderness and pain at the injection site. The most common systemic reactions include headache, fatigue, myalgia, and arthralgia. Other adverse reactions may occur. Vaccination with Flublok Quadrivalent vaccine may not protect all individuals.

INDICATION FOR FLUBLOK QUADRIVALENT VACCINE

Flublok Quadrivalent vaccine is indicated for active immunization against disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. Flublok Quadrivalent vaccine is approved for use in persons 18 years of age and older.

Before administration, please see the full Prescribing Information for Flublok Quadrivalent vaccine.

Flublok Quadrivalent vaccine is manufactured by Protein Sciences Corporation, a Sanofi company, and distributed by Sanofi Pasteur Inc. Flublok Quadrivalent vaccine (CPT®c code 90682) is a covered benefit under Medicare Part B.

cCPT (Current Procedural Terminology) is a registered trademark of the American Medical Association.

References: 1. Flublok Quadrivalent vaccine [Prescribing Information]. Meriden, CT: Protein Sciences Corporation. **2.** Dunkle LM, Izikson R, Patriarca P, et al. Efficacy of recombinant influenza vaccine in adults 50 years of age or older. *N Engl J Med*. 2017;376:2427-2436. **3.** Flublok [press release]. Meriden, CT: Protein Sciences Corporation; October 17, 2017. http://www.proteinsciences.com/FVAC.htm. Accessed January 26, 2018. **4.** Dunkle LM, Izikson R, Post P, Cox MMJ. Introducing modern recombinant technology to the realm of seasonal influenza vaccine: Flublok® for prevention of influenza in adults. *EC Microbiol*. 2015;2:224-234.

Flublok®
QUADRIVALENT
Influenza Vaccine

SANOFI PASTEUR. Discovery Drive. Swiftwater, Pennsylvania 18370. www.sanofipasteur.us
MKT32803-1

2/18

SANOFI PASTEUR